# A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

> **NCT04641975** · PHASE3 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Overactive Bladder (OAB)
- Pharmacokinetics of Mirabegron

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04641975
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-15
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-24
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Termination due to operational futility
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641975, "A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04641975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*